Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Tacrolimus or microemulsified ciclosporin for immunosuppression after liver transplantation?

Nature Clinical Practice Gastroenterology & Hepatology volume 4, pages 424–425 (2007)Cite this article

boxed-textO'Grady J et al. (2007) Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 7: 137–141

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. O'Grady J et al. (2002) Tacrolimus versus microemulsified cyclosporin in liver transplantation: The TMC randomized controlled trial. Lancet 360:1119–1125

    Article  CAS  Google Scholar 

  2. Fung JJ et al. (1996) The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 183: 117–125

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Levy G et al. (2006) 12-Month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transplant 12: 1464–1472

    Article  Google Scholar 

  4. Barenguer M et al. (2007) Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transplant 13: 21–29

    Article  Google Scholar 

  5. Larsen CP et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443–453

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. M Khan is a Fellow in Gastroenterology, AJ Tector is Associate Professor of Surgery and Director of Transplantation Surgery, and PY Kwo is Associate Professor of Medicine and Medical Director of Liver Transplantation at the Indiana School of Medicine, Clarian Health Partners, IN, USA.,

    Mubashir Khan, A Joseph Tector & Paul Y Kwo

Authors
  1. Mubashir Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Joseph Tector
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Y Kwo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Y Kwo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khan, M., Tector, A. & Kwo, P. Tacrolimus or microemulsified ciclosporin for immunosuppression after liver transplantation?. Nat Rev Gastroenterol Hepatol 4, 424–425 (2007). https://doi.org/10.1038/ncpgasthep0874

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0874

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing